Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of ...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September ...
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Merck & Company, with a price target of $170.00. The company’s shares closed yesterday at $141.82. Divan covers ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, ...
The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...
MedPage Today on MSN
Trio of IgA nephropathy drugs proves mettle in interim analyses
Significant proteinuria reductions reported, but still awaiting eGFR data ...
Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results